These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24550570)

  • 1. Continuing education case study quiz.
    Hosp Pharm; 2013 Feb; 48(2):153-5. PubMed ID: 24550570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuing education case study quiz.
    Hosp Pharm; 2013 Mar; 48(3):241-2. PubMed ID: 24421468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuing education case study quiz.
    Hosp Pharm; 2013 Apr; 48(4):332-3. PubMed ID: 24421483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing Education Case Study Quiz.
    Hosp Pharm; 2016 Mar; 51(3):263-265. PubMed ID: 38745582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuing education case study quiz.
    Hosp Pharm; 2013 Jan; 48(1):57-9. PubMed ID: 24550569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linaclotide: a novel approach to the treatment of irritable bowel syndrome.
    Wensel TM; Luthin DR
    Ann Pharmacother; 2011 Dec; 45(12):1535-43. PubMed ID: 22045908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.
    Nee JW; Johnston JM; Shea EP; Walls CE; Tripp K; Shiff S; Fox SM; Bochenek W; Weissman D; Currie MG; Lembo AJ
    Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):397-406. PubMed ID: 30791771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Rothstein RD; Friedenberg FK
    Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
    Shah ED; Kim HM; Schoenfeld P
    Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review.
    Baaleman DF; Gupta S; Benninga MA; Bali N; Vaz KH; Yacob D; Di Lorenzo C; Lu PL
    Paediatr Drugs; 2021 May; 23(3):307-314. PubMed ID: 33876403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
    Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG
    J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study.
    Pohl D; Fried M; Lawrance D; Beck E; Hammer HF
    BMJ Open; 2019 Dec; 9(12):e025627. PubMed ID: 31892640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
    Love BL; Johnson A; Smith LS
    Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland.
    Fisher M; Walker A; Falqués M; Moya M; Rance M; Taylor D; Lindner L
    Eur J Health Econ; 2016 Dec; 17(9):1091-1100. PubMed ID: 26728984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity.
    Carballo F
    Rev Esp Enferm Dig; 2013 Jul; 105(6):345-54. PubMed ID: 24090017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
    Sedky AA; Magdy Y
    Life Sci; 2020 Sep; 256():117960. PubMed ID: 32534033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.